A Four-Week Probiotic Course for Nursing Mothers Reshapes Infant Growth for a Full Year

A short, four-week course of synbiotic supplements taken by breastfeeding mothers during the earliest days of lactation appears to leave a measurable mark on how their infants grow for an entire year, according to a randomized, triple-blind, placebo-controlled trial published in BMC Pediatrics. The study, led by Seyedeh Zalfa Modarresi and Majid Aflatoonian of the Children Growth Disorder Research Center at Shahid Sadoughi University of Medical Sciences in Yazd, Iran, found that babies whose mothers received the supplement maintained a higher weight-for-age z-score than those whose mothers received a placebo, with the gap persisting at both six and twelve months of age. The finding is striking precisely because the intervention was so brief and so indirect: the infants themselves never received anything. Whatever benefit emerged had to travel from mother to child through the complex biological channel of breast milk.

The trial enrolled 96 healthy lactating women, each nursing an exclusively breastfed, full-term infant. Half of the mothers received a synbiotic capsule containing four species of Lactobacillus bacteria combined with fructooligosaccharides, a type of prebiotic fiber that serves as fuel for beneficial microbes. The other half received an identical placebo. Neither the mothers, the researchers, nor the outcome assessors knew who received which preparation, a triple-blind design that guards against the subtle biases that can creep into studies of infant growth, where measurements and expectations can be influenced by knowledge of group assignment. The supplementation period lasted just 28 days, beginning during early lactation, a window when breast milk composition is still actively maturing and when the infant’s gut is being colonized by its first microbial communities.

To track growth, the researchers relied on standardized growth indices used worldwide by pediatricians: the weight-for-age z-score (WAZ), the length-for-age z-score (LAZ), and the head-circumference-for-age z-score (HCAZ). These z-scores express a child’s measurement as a deviation from the average for their age and sex, allowing clinicians to compare growth against international reference standards. Measurements were taken at four points: baseline before supplementation began, immediately after the 28-day intervention, at six months, and at twelve months. The analysis was performed by intention-to-treat, meaning every enrolled participant was analyzed in the group to which they were originally assigned regardless of adherence, and linear mixed models were used to capture growth trajectories over time rather than isolated snapshots.

The headline result concerns weight. At six months, infants in the synbiotic group had a mean weight-for-age z-score of 0.08, compared with −0.63 in the placebo group, a difference that was statistically significant (p = 0.008) and of moderate effect size (Cohen’s d = 0.56). By twelve months, the gap had not closed but instead widened slightly in relative terms: the synbiotic group averaged 0.24 while the placebo group averaged −0.53 (p = 0.001, Cohen’s d = 0.71). In the longitudinal mixed-model analysis, the change in WAZ from baseline was greater in the synbiotic group at six months (β = 0.477; 95% confidence interval, 0.045 to 0.909; p = 0.030) and at twelve months (β = 0.528; 95% confidence interval, 0.093 to 0.963; p = 0.017). In plain terms, a month of maternal supplementation was followed by a small but durable upward shift in the infants’ weight trajectory that lasted throughout the first year of life.

Equally informative is what did not change. Neither length-for-age nor head-circumference-for-age z-scores showed significant differences between the groups at any time point, and the longitudinal trajectories for these two indices were essentially indistinguishable. This selective pattern matters for interpretation. A supplement that uniformly accelerated all growth might raise questions about overfeeding or generalized metabolic stimulation, whereas a weight-specific effect with preserved linear growth and head growth suggests something more nuanced, possibly involving body composition, fat deposition, or the metabolic and inflammatory environment of the infant gut. The authors are careful to note that the underlying biological mechanisms remain unclear, and that no definitive causal pathway can be drawn from these data alone.

One plausible mechanism the investigators specifically tested involves trace minerals. Because certain Lactobacillus species can influence mineral absorption and because manganese, iron, and copper are essential cofactors in infant growth and neurodevelopment, the team measured maternal plasma concentrations of these three metals before and after the supplementation period. The results were negative: maternal plasma manganese, iron, and copper levels were not associated with any of the infant growth indices, either before or after the intervention. This rules out a straightforward mineral-transport explanation and pushes the search for mechanisms toward other candidates, most notably the microbiome-mediated composition of breast milk itself.

That microbiome hypothesis fits into a broader and rapidly evolving body of science. Breast milk is not a sterile fluid but a living ecosystem containing bacteria, human milk oligosaccharides (HMOs), antibodies, hormones, and metabolites. HMOs in particular are indigestible by the infant but serve as selective nutrients for gut bacteria such as Bifidobacterium, shaping the infant microbiome in ways that influence energy harvest from milk, gut barrier integrity, immune programming, and even hormonal signaling. Modifying the maternal gut microbiome with probiotics could, in principle, alter the microbial and oligosaccharide profile of her milk, indirectly recalibrating the infant’s own gut ecology. Fructooligosaccharides in the synbiotic formulation would further feed beneficial bacteria in both the maternal and, via milk components, the infant intestinal environment. Whether such a cascade actually explains the weight differences observed here remains to be demonstrated experimentally.

The trial is not without limitations, and the authors themselves flag the need for caution. The sample size of 96 mother-infant pairs is modest, and the trial was retrospectively registered (IRCT20181020041387N2, registered on 28 June 2024), a detail that trial-methodology specialists typically view as a weakness because retrospective registration can obscure whether outcomes were selected after data collection. The study population consisted of healthy mothers and exclusively breastfed term infants in a single setting, so generalizability to other populations, including preterm infants or mothers unable to breastfeed exclusively, is unknown. The standard deviations of the z-scores were also wide, indicating considerable variability in growth within both groups. And while the effect sizes were moderate, a single trial, however well designed, is rarely sufficient to change clinical practice in an area as sensitive as infant nutrition.

Nevertheless, the study adds a genuinely novel data point to a field where clinical evidence has been limited and inconsistent. Most probiotic research in early life has focused on giving supplements directly to infants or to pregnant women; targeting the lactating mother during the postpartum window is a comparatively underexplored strategy. If confirmed, the approach would be appealing from a public health standpoint: a short, inexpensive, orally administered intervention with no direct exposure of the infant, timed to a period when breast milk is doing its most formative work. The World Health Organization emphasizes breastfeeding as a cornerstone of infant nutrition, and interventions that safely augment its benefits could have meaningful population-level effects on growth patterns in the crucial first year.

The next steps are clear. Larger trials with longer follow-up, direct analysis of milk microbiome and HMO composition, and measurement of infant gut microbial succession would help identify whether the weight-for-age effect is real, reproducible, and mechanistically understood. Until then, the Yazd trial stands as an intriguing proof of concept: that a mother’s microbes, briefly nourished with the right bacteria and fiber, may echo in her child’s growth chart for months afterward. The authors, whose work was supported by Shahid Sadoughi University of Medical Sciences and conducted with the Clinical Research Development Center of Shahid Sadoughi Hospital, conclude that further well-designed studies are needed to confirm the findings and clarify their clinical significance, a measured verdict on a result that, if it holds up, could reshape how scientists think about the microbial handoff between mother and child.

Subject of Research: Effect of maternal synbiotic supplementation during early lactation on infant growth in the first year of life

Article Title: Maternal synbiotic supplementation during early lactation and infant growth in the first year of life: a randomized, triple blind, placebo-controlled trial

Article References: Modarresi, S. Z., Aflatoonian, M., Modaresi, V., Dehghan Niri, H., & Vakili, M. (2026). Maternal synbiotic supplementation during early lactation and infant growth in the first year of life: a randomized, triple blind, placebo-controlled trial. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07866-4

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07866-4

Keywords: synbiotics, probiotics, Lactobacillus, breastfeeding, lactation, infant growth, weight-for-age z-score, gut microbiota, human milk oligosaccharides, randomized controlled trial, trace minerals, maternal nutrition